Randomized Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stents vs. Sirolimus-Eluting Stents for Percutaneous Coronary Intervention in Chronic Total Occlusion – CAtholic Total Occlusion Study (CATOS) Trial –

Hun-Jun Park; Hee-Yeol Kim; Jong-Min Lee; Yoon Seok Choi; Chul-Soo Park; Dong-Bin Kim; Sung Ho Her; Yoon Seok Koh; Mahn Won Park; Beom-June Kwon; Pum Joon Kim; Kiyuk Chang; Wook Sung Chung; Ki-Bae Seung

doi:10.1253/circj.CJ-11-1021

Cardiovascular Intervention

Randomized Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stents vs. Sirolimus-Eluting Stents for Percutaneous Coronary Intervention in Chronic Total Occlusion

– CAtholic Total Occlusion Study (CATOS) Trial –

Hun-Jun Park, Hee-Yeol Kim, Jong-Min Lee, Yoon Seok Choi, Chul-Soo Park, Dong-Bin Kim, Sung Ho Her, Yoon Seok Koh, Mahn Won Park, Beom-June Kwon, Pum Joon Kim, Kiyuk Chang, Wook Sung Chung, Ki-Bae Seung

Author information

Hun-Jun Park
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Hee-Yeol Kim
Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Jong-Min Lee
Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Yoon Seok Choi
Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Chul-Soo Park
Division of Cardiology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Dong-Bin Kim
Division of Cardiology, Department of Internal Medicine, St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul
Sung Ho Her
Division of Cardiology, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Yoon Seok Koh
Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Mahn Won Park
Division of Cardiology, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Beom-June Kwon
Division of Cardiology, Department of Internal Medicine, St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul
Pum Joon Kim
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Kiyuk Chang
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Wook Sung Chung
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
Ki-Bae Seung
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea

Keywords: Chronic total occlusion, Drug-eluting stent, Percutaneous coronary intervention

JOURNAL FREE ACCESS

2012 Volume 76 Issue 4 Pages 868-875

DOI https://doi.org/10.1253/circj.CJ-11-1021

View "Advance Publication" version (January 25, 2012).

Details

Abstract

Background: Limited data are available regarding the direct comparison of angiographic and clinical outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) for chronic total occlusion (CTO). Methods and Results: A prospective, randomized, multicenter trial was conducted to evaluate the non-inferiority of a zotarolimus-eluting stent (ZES; Endeavor Sprint^®, n=80) to a sirolimus-eluting stent (SES; Cypher^®, n=80) in patients with CTO lesion with a reference vessel diameter ≥2.5mm. The primary endpoint was in-segment binary restenosis rate at 9-month angiographic follow-up. Key secondary endpoints included target vessel failure (TVF; including cardiac death, myocardial infarction, and target vessel revascularization) and Academic Research Consortium-defined definite/probable stent thrombosis (ST) within 12 months. The ZES was non-inferior to the SES with respect to the primary endpoint, which occurred in 14.1% (95% confidence interval [CI]: 6.0-22.2) and in 13.7% (95%CI: 5.8-21.6) of patients, respectively (non-inferiority margin, 15.0%; P for non-inferiority <0.001). There were no significant between-group differences in the rate of TVF (10.0% vs. 17.5%; P=0.168) nor in the rate of ST (0.0% vs. 1.3%; P=0.316) during the 12-month clinical follow-up. Conclusions: The effectiveness and safety of ZES are similar to those of SES and therefore it is a good treatment option in patients undergoing PCI for CTO with DESs. (Circ J 2012; 76: 868-875)

Corresponding author

Register with J-STAGE for free!